--- title: "Fate Therapeutics (FATE) news: class action" url: "https://aibio.space/companies/fate-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FATE class action news: Fate Therapeutics faces securities class action and three derivative suits over Janssen disclosures. Fate Therapeutics, Inc." --- FATE Fate Therapeutics, Inc. NASDAQ · United States # Fate Therapeutics (FATE) news FATE class action news Legal · 2026-08-13 ## [Fate Therapeutics faces securities class action and three derivative suits over Janssen disclosures](https://aibio.space/news/fate-therapeutics-faces-securities-class-action-three-derivative-suits/) The 10-Q says Fate and unnamed officers are defendants in a Southern District of California class action. The derivative suits are captioned against Wolchko; board lists come from Fate's 2023 and 2026 proxies. ## Latest Fate Therapeutics news 1. 2025-08-12 Distress [Fate Therapeutics approves restructuring with 12% workforce reduction](https://aibio.space/news/fate-therapeutics-approves-restructuring-12-percent-workforce/) Fate Therapeutics (Nasdaq: FATE) expects $0.9 million to $1.2 million in severance charges in the third quarter of 2025. The company says it has $249 million in cash and investments and a runway through the end of 2027. ## Fate Therapeutics at a glance - **Ticker**: FATE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $153.8 million ### Related companies - [Amgen](https://aibio.space/companies/amgen/) NASDAQ: AMGN - [XBiotech](https://aibio.space/companies/xbiotech/) NASDAQ: XBIT - [Agenus](https://aibio.space/companies/agenus/) NASDAQ: AGEN - [Edgewise Therapeutics](https://aibio.space/companies/edgewise-therapeutics/) NASDAQ: EWTX - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) NASDAQ: SABS - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) NASDAQ: GLSI - [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) NASDAQ: CRBU - [BioStem Technologies](https://aibio.space/companies/biostem-technologies/) NASDAQ: BSEM ### Also on NASDAQ - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) DYN - [Instil Bio](https://aibio.space/companies/instil-bio/) TIL - [Phio Pharmaceuticals](https://aibio.space/companies/phio-pharmaceuticals/) PHIO - [Prothena Corporation](https://aibio.space/companies/prothena/) PRTA - [CASTLE BIOSCIENCES INC](https://aibio.space/companies/castle-biosciences/) CSTL - [20/20 Biolabs](https://aibio.space/companies/20-20-biolabs/) AIDX ## What Fate Therapeutics does Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies. Its platform creates and engineers induced pluripotent stem cells, or iPSCs, into clonal master iPSC lines that serve as a renewable source for manufacturing uniform, multiplexed-engineered T-cell and natural killer cell product candidates. The company says this approach addresses the limits of autologous cell therapies and of viral vectors used to deliver genetic information into patients' T cells. It operates a 40,000+ square foot GMP facility intended to support clinical development and initial commercialization, and it reports over 600 issued patents and 550 pending patent applications for its iPSC platform. Its strategy is to bring these therapies first to patients with autoimmune diseases and cancer. The lead autoimmune program is FT819, an off-the-shelf, iPSC-derived, CD19-targeted CAR T-cell candidate for systemic lupus erythematosus with and without lupus nephritis. A multi-center Phase 1 trial is underway at sites in the United States, the United Kingdom and the European Union, and the FDA granted FT819 regenerative medicine advanced therapy designation in April 2025. | Product or program | What it is | Stage | |---|---|---| | FT819 | Off-the-shelf iPSC-derived CD19-targeted CAR T-cell therapy for systemic lupus erythematosus | Phase 1; RMAT designation granted April 2025 | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/fate-20251231.htm). ## Fate Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$6.6 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | [$13.6 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | | Research and development | [$107.8 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | [$135.0 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | | Net income (loss) | [-$136.3 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | [-$186.3 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | | Cash from operations | [-$106.1 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | [-$122.9 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | | Cash and equivalents | [$46.6 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347988/) | [$36.1 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | | Short-term investments | [$157.0 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347988/) | [$243.0 million](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $32.4 million, plus short-term investments of $121.3 million, $153.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Fate Therapeutics Is there a class action against Fate Therapeutics? Our latest story on this, dated Aug 13, 2026: "Fate Therapeutics faces securities class action and three derivative suits over Janssen disclosures". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fate-therapeutics-faces-securities-class-action-three-derivative-suits/). What is the ticker symbol of Fate Therapeutics? Fate Therapeutics, Inc. trades under the ticker FATE on NASDAQ. Where is Fate Therapeutics listed? Fate Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:F6T; LS:A1W50M; LSX:A1W50M. What is the SEC CIK of Fate Therapeutics? The SEC Central Index Key (CIK) for Fate Therapeutics, Inc. is 1434316. Its filings are on SEC EDGAR. How many shares does Fate Therapeutics have outstanding? 119,820,514 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Fate Therapeutics listed under? Our directory records Fate Therapeutics, Inc. under United States. What does Fate Therapeutics do? Our directory classifies Fate Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Fate Therapeutics? The ISIN recorded for Fate Therapeutics, Inc. is US31189P1021. Does aibio.space cover Fate Therapeutics? aibio.space lists Fate Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does Fate Therapeutics develop? Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies. Its platform creates and engineers induced pluripotent stem cells, or iPSCs, into clonal master iPSC lines that serve as a renewable source for manufacturing uniform, multiplexed-engineered T-cell and natural killer cell product candidates. What is FT819 from Fate Therapeutics? FT819: Off-the-shelf iPSC-derived CD19-targeted CAR T-cell therapy for systemic lupus erythematosus Stage: Phase 1; RMAT designation granted April 2025. What was Fate Therapeutics's revenue last year? $6.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Fate Therapeutics profitable? Fate Therapeutics, Inc. reported a net loss of $136.3 million for the fiscal year ended Dec 31, 2025, and used $106.1 million of cash in operations, per its annual report to the SEC. How much does Fate Therapeutics spend on research and development? $107.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Fate Therapeutics have? $153.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Fate Therapeutics Members talk about Fate Therapeutics (FATE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Fate Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-02-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/fate-20251231.htm) 2. 2025-10-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1434316/000119312525238989/fate-ex99_1.htm) 3. 2025-08-12 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/d452012dex991.htm) 4. 2025-05-30 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/d42374dex991.htm) 5. 2025-03-05 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1434316/000095017025033510/fate-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FATE on TradingView](https://www.tradingview.com/symbols/NASDAQ-FATE/). ## SEC filings and registration - **SEC name**: Fate Therapeutics Inc - **CIK**: 1434316 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: FATE (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131 - **Phone**: 858.875.1803 - **Shares outstanding**: 119,820,514 as of 2026-08-06 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/fate-20260925.htm) filed 2026-09-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347988/fate-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/fate-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/fate-20260612.htm) filed 2026-06-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1434316/000119312526257558/d83385d8k.htm) filed 2026-06-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1434316/000119312526220696/fate-20260331.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/fate-20260513.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1434316/000119312526177094/d949652ddef14a.htm) filed 2026-04-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001434316), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Fate Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FATE, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Fate Therapeutics, Inc. - **Ticker**: FATE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US31189P1021 - **Other listed symbols**: GETTEX:F6T; LS:A1W50M; LSX:A1W50M - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FATE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/fate-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Fate Therapeutics (FATE) news: class action", 2026-10-31, https://aibio.space/companies/fate-therapeutics/